Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2017 ASCO Annual Meeting!


Session: Breast Cancer—Local/Regional/Adjuvant

Type: Oral Abstract Session

Time: Monday June 5, 9:45 AM to 12:45 PM

Location: Hall D2

APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).

Sub-category:
Adjuvant Therapy

Category:
Breast Cancer—Local/Regional/Adjuvant

Meeting:
2017 ASCO Annual Meeting

Abstract No:
LBA500

Citation:
J Clin Oncol 35, 2017 (suppl; abstr LBA500)

Author(s): Gunter Von Minckwitz, Marion Jennifer Procter, Evandro De Azambuja, Dimitrios Zardavas, Adam Knott, Giuseppe Viale, Thomas M. Suter, Amal Arahmani, Nathalie Rouchet, Emma Clark, Mark Benyunes, Istvan Lang, Christelle Levy, Denise A. Yardley, Jose Bines, Richard D. Gelber, Martine J. Piccart-Gebhart, Jose Baselga; German Breast Group (GBG), Neu-Isenburg, Germany; Frontier Science (Scotland) Ltd., Kingussie, United Kingdom; Institut Jules Bordet, Brussels, Belgium; Breast International Group, Brussels, Belgium; Roche Products, Ltd., Welwyn, United Kingdom; Department of Pathology, European Institute of Oncology and University of Milan, Milan, Italy; University Hospital Bern, Bern, Switzerland; Genentech, Inc., San Francisco, CA; National Institute of Oncology, Budapest, Hungary; Centre François Baclesse, Caen, France; Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; National Cancer Institute, Rio de Janeiro, Brazil; Dana-Farber Cancer Institute, Boston, MA; Jules Bordet Institute, Brussels, Belgium; Memorial Sloan Kettering Cancer Center, New York, NY

Abstract Disclosures

Abstract:

Background: In previous trials P significantly prolonged progression free and overall survival and increased pCR rates when added to T+C in pts with HER2-positive breast cancer (BC). The APHINITY trial was designed to test whether the addition of P to adjuvant T+C improves pt outcomes. Methods: Pts with adequately excised HER2-positive, pT1-3 EBC were randomly assigned to receive standard adjuvant C plus one year of either T + P or T + Pla. Eligible pts had either node-positive disease, or node-negative disease (pN0) and a tumor size of > 1.0 cm. Pts with pN0, T1b tumors with high risk features were initially eligible. The primary efficacy endpoint was invasive disease-free survival (IDFS); we assumed a 3-year IDFS of 91.8% with P and 89,.2% with Pla. Results: 4805 pts were randomized to C and T plus either P (n = 2400) or Pla (n = 2405). Baseline demographics and tumor characteristics between the arms were well balanced, with 63% and 36% of pts having node-positive and hormone receptor negative EBC respectively. P and Pla treatments were completed in 84.5% and 87.4% of patients, respectively. IDFS events occurred in 171 (7.1%) P pts and 210 (8.7%) Pla pts (hazard ratio (HR) 0.81 (95% CI 0.68-1.00), P = 0.045). Estimates of IDFS at 3 years were 94.1% and 93.2% in the P and Pla arms, respectively. The node-positive cohort had a 3-year IDFS rate of 92.0% for P compared with 90.2% for Pla (HR 0.77 (95% CI 0.62-0.96), P = 0.019). The pN0 cohort had a 3-year IDFS rate of 97.5% for P and 98.4% for Pla; HR = 1.13 (95% CI 0.68-1.86). The safety profile of P was consistent with previous trials. For the primary cardiac endpoint (heart failure or cardiac death) and secondary cardiac endpoint (asymptomatic or mildly symptomatic LVEF decline) rates were low, 0.7% vs 0.3% and 2.7% vs 2.8%, in the P and Pla arms, respectively. Diarrhea grade ≥3 was more frequent with P (9.9% vs 3.7%). Conclusions: The APHINITY trial met its primary endpoint: P significantly improved IDFS in patients with HER2-positive EBC when added to T+C. No new safety signals were identified. Clinical trial information: NCT01358877

 
Other Abstracts in this Sub-Category:

 

1. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.

Meeting: 2017 ASCO Annual Meeting Abstract No: 501 First Author: Pier Franco Conte
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

2. Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer.

Meeting: 2017 ASCO Annual Meeting Abstract No: 502 First Author: Alvaro Moreno-Aspitia
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

3. SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC).

Meeting: 2017 ASCO Annual Meeting Abstract No: 503 First Author: Marco Colleoni
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

More...